Exelixis, Inc. (ticker: EXEL, exchange: NASDAQ Global Market (.O))
News Release -
Exelixis Announces February 10 Webcast of Presentation at the 11th Annual BIO CEO & Investor Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
Exelixis, Inc. (Nasdaq:EXEL) announced today that Frank Karbe, the
company's Executive Vice President and Chief Financial Officer, will
present at the 11th Annual BIO CEO & Investor Conference at
2:45 p.m. EST/11:45 a.m. PST on Tuesday, February 10, 2009. Mr. Karbe
will discuss the company's development pipeline and corporate strategy.
The presentation will be webcast and may be accessed in the Event
Calendar page under Investors on the Exelixis website at www.exelixis.com.
Exelixis, Inc. is a development-stage biotechnology company dedicated to
the discovery and development of novel small molecule therapeutics for
the treatment of cancer and other serious diseases. The company is
leveraging its fully integrated drug discovery platform to fuel the
growth of its development pipeline, which is primarily focused on
cancer. Currently, Exelixis' broad product pipeline includes
investigational compounds in phase 3, phase 2, and phase 1 clinical
development. Exelixis has established strategic corporate alliances with
major pharmaceutical and biotechnology companies, including
Bristol-Myers Squibb, GlaxoSmithKline, Genentech, Wyeth Pharmaceuticals,
and Daiichi-Sankyo. For more information, please visit the company's web
site at www.exelixis.com.
Exelixis and the Exelixis logo are registered U.S. trademarks.
Source: Exelixis, Inc.
Charles Butler, 650-837-7277 (Investors)
& Investor Relations
Maxwell Harrison, 650-837-7012 (Media)